Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins sits in the top decile of US sponsors by registered trial count (#69 of 15,742 sponsors by registered trial count).
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins: 523 sponsored US clinical trials, 69 recruiting.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins sponsors 523 registered US clinical trials on ClinicalTrials.gov, 69 of them currently recruiting, and 301 completed. 5 of these trials are in Phase 3-4 (later-stage) and 395 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 17 trials.
Top-decile sponsor footprint
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins ranks in the top decile of sponsors by registered trial count (#69 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
301 of 415 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (72.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
523 total, page 7 of 11
A Phase 1 Trial of TST of PD 0332991 Followed by Cytarabine and Mitoxantrone for Adults With Relapsed and Refractory Acute Leukemias and High-Risk Myelodysplasia
NCT01701375
Prospective Evaluation of T-cell Immune Status in Patients With Newly Diagnosed High Grade Gliomas
NCT02041611
Pre-Prostatectomy Lovastatin on Prostate Cancer
NCT01478828
Feasibility of Lymphocyte Reinfusion in Newly Diagnosed High Grade Gliomas
NCT01653834
Mibefradil Dihydrochloride and Temozolomide in Treating Patients With Recurrent Glioma
NCT01480050
Johns Hopkins Breast Cancer Program Hormone Therapy Longitudinal Database
NCT01937052
Study of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With Adenocarcinoma.
NCT01578551
PET Quantitative Assessments of Solid Tumor Response to Immune Checkpoint Blockade Therapy
NCT01666353
Safety Study of HPV DNA Vaccine to Treat Head and Neck Cancer Patients
NCT01493154
Administration of Tadalafil in Conjunction With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma
NCT01374217
A Trial of Oral 5-azacitidine in Combination With Romidepsin in Advanced Solid Tumors, With an Expansion Cohort in Virally Mediated Cancers and Liposarcoma
NCT01537744
Allogeneic GM-CSF Vaccine and Lenalidomide in Treating Myeloma Patients With Near Complete Remission
NCT01349569
A Feasibility Study of a Modular Video Augmentation System for Image-Guided Skull Base Surgery
NCT01591954
Neural Progenitor Cell Sparing Radiation Therapy Plus Temozolomide
NCT01478854
Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma
NCT01431794
Gemcitabine/Taxotere/Xeloda (GTX) With Cisplatin in Subjects With Metastatic Pancreatic Cancer
NCT01459614
Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma
NCT01438554
Safety Study of a Melanoma Vaccine (GVAX) With or Without Cyclophosphamide in Patients With Surgically Resected Melanoma
NCT01435499
Decision Support for Women With Breast Cancer
NCT01447771
Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide
NCT01342289
Effects of Two Doses of MPX Capsules on Rising Prostate-specific Antigen Levels in Men Following Initial Therapy for Prostate Cancer
NCT01317199
Endothelial Function, Arterial Stiffness and Components
NCT01439217
CHFR Methylation Status Esophageal Cancer Study
NCT01372202
Bone Marrow Transplant Trial for Patients With Refractory Severe Aplastic Anemia
NCT01383434
Evaluation of a Transrectal Scintigraphic Detector(ProxiScanTM) for Detection of Primary Prostate Cancer
NCT01359189
Patient-donor Vaccination in the Context of Allogeneic Bone Marrow Transplant With Post-transplant Cyclophosphamide
NCT01282216
A Study of Vorinostat and Tamoxifen in Newly Diagnosed Breast Cancer
NCT01194427
Intra-arterial Chemotherapy for the Treatment of Intraocular Retinoblastoma
NCT01293539
Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal Symptoms
NCT01194440
Trial of ICM With or Without AZD2281 (Olaparib) in Patients With Advanced Pancreatic Cancer
NCT01296763
124I-FIAU Imaging in EBV and KSHV Associated Cancers
NCT00982449
Study of High-Dose-Rate Endorectal Brachytherapy (HDRBT) in the Treatment of Locally Advanced Low Rectal Cancer
NCT01226979
Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas
NCT01088815
Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies
NCT01203722
Biodistribution and Pharmacokinetic Study of 18F-DCFBC Prostate Specific Membrane Antigen Based PET in Patients With Advanced Prostate Cancer
NCT01417182
Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers
NCT01135329
Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme
NCT00895180
Study of Recurrent Prostate Cancer With Rising Prostate Specific Antigen (PSA)
NCT01118741
Treatment De-Intensification for Squamous Cell Carcinoma of the Oropharynx
NCT01088802
A Pilot Study of Parenteral Testosterone and Oral Etoposide as Therapy for Men With Castration Resistant Prostate Cancer
NCT01084759
An Early Safety and Efficacy Study of Ascites Management: Standard Paracentesis or Early Intervention With Pleurx Catheters in Patients With Malignant Ascites
NCT01077063
Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic Granulocyte Macrophage Colony-stimulating Factor (GM-CSF)-Based Myeloma Cellular Vaccine in the Autologous Transplant Setting in Multiple Myeloma
NCT01045460
Cytokine Expression During Radiation for Breast Cancer
NCT00836186
RAD001 in Combination With Cetuximab and Cisplatin in Recurrent and Metastatic SCCHN
NCT01009346
Using High Resolution Function Imaging To Detect Melanoma and Dysplastic Nevi
NCT01118832
Therapeutic Vaccination for Patients With HPV16+ Cervical Intraepithelial Neoplasia (CIN2/3)
NCT00988559
Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma
NCT00949325
ABT-888, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
NCT00770471
Cyclophosphamide and Vaccine Therapy With or Without Trastuzumab in Treating Patients With Metastatic Breast Cancer
NCT00971737
Optimized Donor Selection, Nonmyeloablative BMT for B-cell Lymphomas With Post-transplantation Cy and Rituximab
NCT00946023
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 185 |
| Phase 2 | 210 |
| Phase 3 | 5 |
Therapeutic Areas
What is open in the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins pipeline
69 recruiting of 523 indexed (13% open); 301 completed (58%).
Phase mix: 5 late (III/IV) vs 395 early (I/II) (early-phase heavy).
Top condition: Prostate Cancer (17 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins: open-pipeline peers nationwide
Peers matched on 523 registered trials and 13% open enrollment, not the therapeutic-area sidebar.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 523 trials (± recruiting share)
- AbbVie · 526 trials · 21% recruiting
- Boehringer Ingelheim · 515 trials · 8% recruiting
- Gilead Sciences · 504 trials · 5% recruiting
- H. Lee Moffitt Cancer Center and Research Institute · 502 trials · 16% recruiting
Sponsors near 13% open enrollment (± trial volume)
- MetroHealth Medical Center · 13% recruiting · 76 trials
- Texas Tech University Health Sciences Center · 13% recruiting · 76 trials
- Chiesi Farmaceutici S.p.A. · 13% recruiting · 30 trials
- Dizal Pharmaceuticals · 13% recruiting · 15 trials
Related
What to do with this Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins page
523 registered trials is a research-attention snapshot, not an endorsement of Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins or any single study.
- 69 of Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Prostate Cancer is the condition Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins pipeline card: 523 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.